Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients.

Journal of viral hepatitis - 1 Jul 2011

Zhang X, Lin S M, Ye F, Chen T Y, Liu M, Chen Y R, Zheng S Q, Zhao Y R, Zhang S L

Abstract excerpt

Quantification of HBeAg levels has been found to be useful in monitoring and predicting the outcomes of interferon and lamivudine treatment in HBeAg-positive patients. The aim of this study was to determine whether quantification of HBeAg at baseline and on treatment could predict which patients would achieve HBeAg seroconversion after 96 weeks of entecavir therapy. Sixty-five HBeAg-positive naïve chronic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to DNA, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Share to Polymerase Chain Reaction

Share to Treatment Outcome

Source

Identifiers

PMID: 21692931
DOI: 10.1111/j.1365-2893.2010.01423.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients.PMID 21692931Read ↗

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.Semantic proximity Read ↗

Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.Semantic proximity Read ↗

Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.Semantic proximity Read ↗

Early hepatitis B surface antigen decline predicts treatment response to entecavir in patients with chronic hepatitis B.Semantic proximity Read ↗

Quantitation of HBsAg predicts response to entecavir therapy in HBV genotype C patients.Semantic proximity Read ↗

[Efficacy and predictors of the virologic response to entecavir therapy in nucleoside-naive patients with chronic hepatitis B].Semantic proximity Read ↗

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.Semantic proximity Read ↗

Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.Semantic proximity Read ↗

Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.Semantic proximity Read ↗

Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?Semantic proximity Read ↗

[Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].Semantic proximity Read ↗

Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.